Literature DB >> 26189768

Subsequent Malignant Neoplasms in a Population-Based Cohort of Pediatric Cancer Patients: A Focus on the First 5 Years.

Jason D Pole1, Lan Ying Gu2, Victoria Kirsh3, Mark L Greenberg4, Paul C Nathan5.   

Abstract

BACKGROUND: The purpose was to describe the development of subsequent malignant neoplasms (SMN) among a population-based cohort of pediatric cancer patients, with a focus on SMNs that occurred within the first 5 years from diagnosis.
METHODS: The cohort was identified from POGONIS, an active provincial registry. Cohort members were Ontario residents ages 0 to 14.9 years at primary diagnosis between January 1985 and December 2008. SMNs that developed <18 years were captured by POGONIS, whereas SMNs diagnosed later were identified through linkage. Cumulative incidence and standardized incidence ratios (SIR) were calculated, and proportional hazards models were estimated to examine factors associated with SMN development.
RESULTS: A total of 7,920 patients were eligible. 2.4% (188/7,920) developed 197 SMNs. Mean follow-up time was 10.7 years (SD = 7.6 years; range, 0.0-26.4 years) with mean time to SMN of 8.5 years (SD = 6.3 years; range, 0.0-24.9 years). The SIR for the development of a SMN was 9.9 [95% confidence interval (CI), 8.6-11.4]. 40.6% of SMNs (80/197) developed within 5 years. Early SMNs were more likely to be leukemia and lymphoma. Factors associated with early SMN were primary diagnosis of a bone tumor (OR, 4.88; 95% CI, 1.52-15.60), exposure to radiotherapy (OR, 1.82; 95% CI, 1.02-3.22), and the highest dose of epipodophyllotoxin (OR, 3.74; 95% CI, 1.88-7.42).
CONCLUSIONS: Over 40% of SMNs diagnosed in childhood cancer patients occurred in the first 5 years after diagnosis, suggesting a need for early and ongoing surveillance. IMPACT: The early development of certain SMNs reinforces the need for early and continued surveillance at all stages for pediatric cancer patients. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 26189768     DOI: 10.1158/1055-9965.EPI-15-0360

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  6 in total

1.  Temporal Trends in Treatment and Subsequent Neoplasm Risk Among 5-Year Survivors of Childhood Cancer, 1970-2015.

Authors:  Lucie M Turcotte; Qi Liu; Yutaka Yasui; Michael A Arnold; Sue Hammond; Rebecca M Howell; Susan A Smith; Rita E Weathers; Tara O Henderson; Todd M Gibson; Wendy Leisenring; Gregory T Armstrong; Leslie L Robison; Joseph P Neglia
Journal:  JAMA       Date:  2017-02-28       Impact factor: 56.272

2.  A comparison of two models of follow-up care for adult survivors of childhood cancer.

Authors:  K Reynolds; M Spavor; Y Brandelli; C Kwok; Y Li; M Disciglio; L E Carlson; F Schulte; R Anderson; P Grundy; J Giese-Davis
Journal:  J Cancer Surviv       Date:  2019-06-27       Impact factor: 4.442

3.  Hospitalization and mortality outcomes in the first 5 years after a childhood cancer diagnosis: a population-based study.

Authors:  Angela Steineck; Eric J Chow; David R Doody; Beth A Mueller
Journal:  Cancer Causes Control       Date:  2021-04-09       Impact factor: 2.532

4.  Temporal clustering of neuroblastic tumours in children and young adults from Ontario, Canada.

Authors:  Louise Hayes; Nermine Basta; Colin R Muirhead; Jason D Pole; Paul Gibson; Bruna Di Monte; Meredith S Irwin; Mark Greenberg; Deborah A Tweddle; Richard J Q McNally
Journal:  Environ Health       Date:  2022-03-07       Impact factor: 5.984

5.  Large Population Analysis of Secondary Cancers in Pediatric Leukemia Survivors.

Authors:  Siddhartha Yavvari; Yasaswi Makena; Sahithi Sukhavasi; Monish Ram Makena
Journal:  Children (Basel)       Date:  2019-11-29

6.  Risk of a second cancer in Canadians diagnosed with a first cancer in childhood or adolescence.

Authors:  Dianne Zakaria; Amanda Shaw; Lin Xie
Journal:  EClinicalMedicine       Date:  2019-10-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.